1-MonopalmitinCAS# 542-44-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 542-44-9 | SDF | Download SDF |
PubChem ID | 14900 | Appearance | Powder |
Formula | C19H38O4 | M.Wt | 330.50 |
Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 2,3-dihydroxypropyl hexadecanoate | ||
SMILES | CCCCCCCCCCCCCCCC(=O)OCC(CO)O | ||
Standard InChIKey | QHZLMUACJMDIAE-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C19H38O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(22)23-17-18(21)16-20/h18,20-21H,2-17H2,1H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 1-Monopalmitin has dielectric properties. 2. 1-Monopalmitin inhibits the P-glycoprotein activity in intestinal Caco-2 cells. |
Targets | P-gp |
1-Monopalmitin Dilution Calculator
1-Monopalmitin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.0257 mL | 15.1286 mL | 30.2572 mL | 60.5144 mL | 75.643 mL |
5 mM | 0.6051 mL | 3.0257 mL | 6.0514 mL | 12.1029 mL | 15.1286 mL |
10 mM | 0.3026 mL | 1.5129 mL | 3.0257 mL | 6.0514 mL | 7.5643 mL |
50 mM | 0.0605 mL | 0.3026 mL | 0.6051 mL | 1.2103 mL | 1.5129 mL |
100 mM | 0.0303 mL | 0.1513 mL | 0.3026 mL | 0.6051 mL | 0.7564 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Apilimod
Catalog No.:BCC5286
CAS No.:541550-19-0
- Vicriviroc Malate
Catalog No.:BCC1230
CAS No.:541503-81-5
- Flecainide acetate
Catalog No.:BCC1578
CAS No.:54143-56-5
- Neoisoastilbin
Catalog No.:BCN6532
CAS No.:54141-72-9
- Apoptosis Inhibitor
Catalog No.:BCC1143
CAS No.:54135-60-3
- 9-Benzylcarbazole-3-carboxaldehyde
Catalog No.:BCC8800
CAS No.:54117-37-2
- 15-Hydroxydehydroabietic acid
Catalog No.:BCN5720
CAS No.:54113-95-0
- Muscone
Catalog No.:BCN6275
CAS No.:541-91-3
- Isovaleramide
Catalog No.:BCC4668
CAS No.:541-46-8
- Decamethonium Bromide
Catalog No.:BCC4568
CAS No.:541-22-0
- L-Carnitine inner salt
Catalog No.:BCN1229
CAS No.:541-15-1
- 2-(1-Hydroxy-1-methylethyl)-4-methoxy-7H-furo[3,2-g][1]benzopyran-7-one
Catalog No.:BCN1422
CAS No.:54087-32-0
- Cimaterol
Catalog No.:BCC6647
CAS No.:54239-37-1
- 3-Benzoylpyridine
Catalog No.:BCC8623
CAS No.:5424-19-1
- Stachyose trihydrate
Catalog No.:BCN8361
CAS No.:54261-98-2
- (+)-Fluprostenol
Catalog No.:BCC7947
CAS No.:54276-17-4
- 2',4'-Dihydroxy-3',6'-dimethoxydihydrochalcone
Catalog No.:BCN1421
CAS No.:54299-52-4
- Ac-Gly-OH
Catalog No.:BCC2943
CAS No.:543-24-8
- Amsacrine hydrochloride
Catalog No.:BCC4310
CAS No.:54301-15-4
- Protopseudohypericin
Catalog No.:BCN2813
CAS No.:54328-09-5
- 4beta-Hydroxywithanolide E
Catalog No.:BCN7572
CAS No.:54334-04-2
- Eriodictyol 7,3'-dimethyl ether
Catalog No.:BCN8105
CAS No.:54352-60-2
- Decarine
Catalog No.:BCN5721
CAS No.:54354-62-0
- 4'-Methoxyacetoacetanilide
Catalog No.:BCC8712
CAS No.:5437-98-9
A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound.[Pubmed:15630255]
Biofactors. 2004;22(1-4):71-4.
P-glycoprotein (P-gp) is a 170 kDa membrane protein that belongs to the ATP-binding cassette (ABC) transporter superfamily. In normal tissues, P-gp functions as an ATP-dependent efflux pump that excretes highly hydrophobic xenobiotic compounds, playing an important role in protecting the cells/tissues from xenobiotics. In the present study, chemical substances that could directly modulate the intestinal P-gp activity were searched in vegetables and fruits. By using human intestinal epithelial Caco-2 cells as a model of the small intestinal cells, we observed that a bitter melon fraction extracted from 40% methanol showed the greatest increase of the rhodamine-123 accumulation by Caco-2 cells. Inhibitory compounds in the bitter melon fraction were then isolated by HPLC using Pegasil C4 and Pegasil ODS columns. The HPLC fraction having the highest activity was analyzed by (1)H-NMR and FAB-MS, and the active compound was identified as 1-Monopalmitin. It is interesting that certain types of monoglyceride might be involved in the drug bioavailability by specifically inhibiting the efflux mediated by P-gp.